Stoke Therapeutics Inc [STOK] stock prices are down -0.70% to $12.76 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The STOK shares have lost -0.43% over the last week, with a monthly amount glided 76.73%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, April 2024, Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference. In a post published today on Yahoo Finance, Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on March 26, 2024, when TD Cowen upgraded its rating to a Outperform. On July 25, 2023, downgrade downgraded it’s rating to Market Perform. BofA Securities upgraded its rating to a Neutral and increased its price target to $12 on May 01, 2023. BofA Securities downgraded its rating to Underperform for this stock on January 06, 2023, and downed its price target to $9. In a note dated October 24, 2022, SVB Leerink upgraded an Outperform rating on this stock but restated the target price of $30.
The stock price of Stoke Therapeutics Inc [STOK] has been fluctuating between $3.35 and $16.40 over the past year. Currently, Wall Street analysts expect the stock to reach $33.67 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $12.76 at the most recent close of the market. An investor can expect a potential return of 163.87% based on the average STOK price forecast.
Analyzing the STOK fundamentals
The Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 8.78M for trailing twelve months, representing a drop of -14.29%. Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at -12.59%, Pretax Profit Margin comes in at -11.92%, and Net Profit Margin reading is -11.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.55 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.30 points at the first support level, and at 11.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.11, and for the 2nd resistance point, it is at 13.47.
Stoke Therapeutics Inc [STOK] reported earnings per share of -$0.6 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.63/share, meaning a difference of $0.03 and a surprise factor of 4.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.55 per share as compared to estimates of -$0.63 per share, a difference of $0.08 representing a surprise of 12.70%.
Ratios To Look Out For
It’s worth pointing out that Stoke Therapeutics Inc [NASDAQ:STOK]’s Current Ratio is 6.99. On the other hand, the Quick Ratio is 6.99, and the Cash Ratio is 6.21. Considering the valuation of this stock, the price to sales ratio is 75.37, the price to book ratio is 3.67.
Transactions by insiders
Recent insider trading involved Nash Huw M., COO & CBO, that happened on Apr 01 ’24 when 61329.0 shares were sold. CHIEF MEDICAL OFFICER, Ticho Barry completed a deal on Apr 01 ’24 to sell 9426.0 shares. Meanwhile, GENERAL COUNSEL & CORP SEC Allan Jonathan sold 5126.0 shares on Mar 28 ’24.
